Prevalence of and severity of lower urinary tract symptoms (LUTS) according to male sexual orientation have been scantly analysed. We aimed to assess the prevalence and severity of LUTS in a cohort of Caucasian-European men who have sex with men seeking medical help for uroandrologic reasons other than LUTS.
Data from 949 consecutive individuals in an outpatient setting were analysed. Severity of LUTS was measured with the International Prostate Symptom Score (IPSS). Men with storage symptoms scored 1-3 and ⩾4 (of 15), and voiding symptoms scored 1-4 and ⩾5 (of 20) were considered as having mild and moderate-to-severe symptoms, respectively. For individual symptoms, patients with scores ⩾1 were deemed symptomatic (according to Apostolidis et al. (15)). Descriptive statistics and logistic regression models tested the association between LUTS and sexual orientation.
Complete data were available for 213 (22. 4%) men who have sex with men (MSM) and 736 (77. 6%) heterosexuals (mean age (s. d. ): 41. 0 (12. 2) vs 39. 9 (12. 1) years). Compared with heterosexuals, MSM reported higher rates of total IPSS scores suggestive of moderate (21. 6% vs 20%) and severe LUTS (3. 8% vs 2. 4%) (P=0. 004). Similarly, MSM showed higher rates of mild (48. 8% vs 45. 2%) and moderate-to-severe (39. 4% vs 30. 4%) storage symptoms (all P
These findings suggest a higher prevalence and severity of LUTS in MSM compared with heterosexual men seeking medical help for uroandrologic reasons other than LUTS. Prostate Cancer and Prostatic Diseases advance online publication, 29 September 2015; doi:10. 1038/pcan. 2015. 41.
Prostate cancer and prostatic diseases. 2015 Sep 29 [Epub ahead of print]
L Boeri, P Capogrosso, E Ventimiglia, A Serino, G La Croce, A Russo, G Castagna, R Scano, A Briganti, R Damiano, F Montorsi, A Salonia
Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy. , Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy. , Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy. , Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy. , Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy. , Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy. , Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy. , Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy. , Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy. , Research Doctorate Program in Urology, Magna Graecia University, Catanzaro, Italy. , Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy. , Division of Experimental Oncology/Unit of Urology, URI-Urological Research Institute, University Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy.